ArticleProceedings of the National Academy of Sciences of the United States of America1999
Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Engineering multiple levels of specificity in an RNA viral vector.Nature communications · 2026Article
- Targeting lentiviral vectors to primordial germ cells (PGCs): An efficient strategy for generating transgenic chickens.Zoological research · 2020Article
- Retargeting Lentiviruses via SpyCatcher-SpyTag Chemistry for Gene Delivery into Specific Cell Types.mBio · 2017Article
- Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration.PLoS pathogens · 2015Article
- Selective viral vector transduction of ErbB4 expressing cortical interneurons in vivo with a viral receptor-ligand bridge protein.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Lentiviral vectors for immune cells targeting.Immunopharmacology and immunotoxicology · 2010Review
- Targeting lentiviral vector to specific cell types through surface displayed single chain antibody and fusogenic molecule.Virology journal · 2010Article
- Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus.Retrovirology · 2010Article
- A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide.The journal of gene medicine · 2009Article
- Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins.The journal of gene medicine · 2009Article
- Engineering fusogenic molecules to achieve targeted transduction of enveloped lentiviral vectors.Journal of biological engineering · 2009Article
- Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule.Pharmaceutical research · 2009Article
- Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles.Journal of virology · 2008Article
- The host cell sulfonation pathway contributes to retroviral infection at a step coincident with provirus establishment.PLoS pathogens · 2008Article
- Gamma-retroviral vectors enveloped with an antibody and an engineered fusogenic protein achieved antigen-specific targeting.Biotechnology and bioengineering · 2008Article
- Monosynaptic restriction of transsynaptic tracing from single, genetically targeted neurons.Neuron · 2007Article
- Article
- Targeting lentiviral vectors to specific cell types in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Lentiviral-mediated delivery of siRNAs for antiviral therapy.Gene therapy · 2006Review
- Antiviral applications of RNAi.Handbook of experimental pharmacology · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Successful targeting methods represent a major hurdle to the use of retroviral vectors in cell-specific gene-delivery applications. We recently described an approach for retroviral targeting with a retroviral receptor-ligand bridge protein that was bound to the cognate cell-surface ligand receptors before viral challenge. We now report a significant improvement made to this viral targeting method by using a related bridge protein, designated TVB-EGF, comprised of the extracellular domain of the TVB receptor for subgroup B avian leukosis virus fused to epidermal growth factor (EGF). The most important activity of TVB-EGF was that it allowed specific viral entry when preloaded onto virions. Furthermore, virions preloaded with TVB-EGF were thermostable and could be produced directly from virus- packaging cells. These data suggest an approach for targeting retroviral vectors to specific cell types by using virions preloaded with a retroviral receptor-ligand bridge protein and indicate that these types of bridge proteins may be useful reagents for studying the normal mechanism of retroviral entry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.